Inefficient repair of tamoxifen-DNA adducts in rats and mice

Drug Metabolism and Disposition

Volumn 34, Issue 2, 2006, Pages 311-317

  Sung, Yeon Kim ^a   Suzuki, Naomi ^a   Santosh Laxmi, Y R ^a   Shibutani, Shinya ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; DNA ADDUCT; DNA REPAIR; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG LABELING; EXCISION REPAIR; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; MONITORING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; RODENT; STRUCTURE ANALYSIS; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DNA ADDUCTS; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; LIVER; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; RATS; RATS, INBRED F344; SPECIES SPECIFICITY; TAMOXIFEN; TISSUE DISTRIBUTION;

ANIMALIA; RODENTIA;

EID: 31344466796     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.007013     Document Type: Article

References (40)

1. 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J Natl Cancer Inst 96:1099-1104.
2. Carmichael PL, Ugwumadu AH, Neven P, Hewer AJ, Poon GK, and Phillips DH (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56:1475-1479.
3. Cerutti P, Shinohara K, and Remsen J (1997) Repair of DNA damage induced by ionizing radiation and benzo[a]pyrene in mammalian cells. J Toxicol Environ Health 2:1375-1386.
4. da Costa GG, McDaniel-Hamilton LP, Heflich RH, Marques MM, and Beland FA (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 22:1307-1315.
5. Dasaradhi L and Shibutani S (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem Res Toxicol 10:189-196.
6. Davies R, Gant TW, Smith LL, and Styles JA (1999) Tamoxifen induces G:C→T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not 5′-CpG-3′ dinucleotide sequences as found in the lacI transgene. Carcinogenesis 20:1351-1356.
7. 32P-postlabeling. Cancer Res 59:4829-4833.
8. Fischer B, Costantino JP, Wickerham L, Redmond CK, Kavanah M, Cronin WM, Botel V, Robidoux A, Dimitrov N, Atkins J, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
9. 2-AAF). Chem Res Toxicol 10:1123-1132.
10. Greaves P, Goonetilleke R, Nunn G, Topham J, and Orton T (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wister-derived rats. Cancer Res 53:3919-3924.
11. Hachisuga T, Tsujioka H, Horiuchi S, Udou T, Emoto M, and Kawarabayashi T (2005) K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene. Br J Cancer 92:1098-1103.
12. Han X and Liehr JG (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52:1360-1363.
13. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, and Williams GM (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 53:4534-4541.
14. Howard PC, Casciano DA, Beland FA, and Shaddock JG (1981) The binding of N-hydroxy-2-acetylaminofluorene to DNA and repair of the adducts in primary rat hepatocyte cultures. Carcinogenesis 2:97-102.
15. Kim SY, Suzuki N, Laxmi YRS, and Shibutani S (2004) Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev 36:199-218.
16. Martin EA, Brown K, Gaskell M, Al-Azzawi F, Garner RC, Boocock DJ, Mattock E, Pring DW, Dingley K, Turteltaub KW, et al. (2003) Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res 63:8461-8465.
17. Martin EA, Carthew P, White IN, Heydon RT, Gaskell M, Mauthe RJ, Turteltaub KW, and Smith LL (1997) Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis 18:2209-2215.
18. McLuckie KI, Crookston RJ, Gaskell M, Farmer PB, Routledge MN, Martine EA, and Brown K (2005) Mutation spectra induced by α-acetoxytamoxifen-DNA adducts in human DNA repair proficient and deficient (xeroderma pigmentosum complementation group A) cells. Biochemistry 44:8198-8205.
19. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1617.
20. Osborne MR, Hewer A, Hardcastle IR, Carmichael PL, and Phillips DH (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res 56:66-71.
21. Phillips DH, Hewer A, Osborne MR, Cole KJ, Churchill C, and Arlt VM (2005) Organ specificity of DNA adduct formation by tamoxifen and α-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and human risk assessment. Mutagenesis 20:297-303.
22. Rajaniemi H, Rasanen I, Koivisto P, Peltonen K, and Hemminki K (1999) Identification of the major tamoxifen-DNA adducts in rat liver by mass spectroscopy. Carcinogenesis 20:305-309.
23. Sands AT, Abuin A, Sanchez A, Conti CJ, and Bradley A (1995) High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature (Lond) 14:162-165.
24. 2-2′-deoxyguanosinyl)tamoxifen by phosphoramidite chemical synthesis. Chem Res Toxicol 15:218-225.
25. Schild LJ, Divi RL, Beland FA, Churchwell MI, Doerge DR, Gamboa da Costa G, Marques MM, and Poirier MC (2003) Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res 63:5999-6003.
26. Shibutani S, Dasaradhi L, Terashima I, Banoglu E, and Duffel MW (1998a) α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res 58:647-653.
27. Shibutani S, Ravindernath A, Suzuki N, Terashima I, Sugarman SM, Grollman AP, and Pearl ML (2000a) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21:1461-1467.
28. Shibutani S, Reardon JT, Suzuki N, and Sancar A (2000b) Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system. Cancer Res 60:2607-2610.
29. Shibutani S, Shaw P, Suzuki N, Dasaradhi L, Duffel MW, and Terashima I (1998b) Sulfation of α-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen DNA adducts. Carcinogenesis 19:2007-2011.
30. Shibutani S, Suzuki N, Laxmi YRS, Schild LJ, Divi LJ, Divi RL, Grollman AP, and Poirier MC (2003) Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res 63:4402-4406.
31. Shimotakahara S, Gorin A, Kolbanovskiy A, Kettani A, Hingerty BE, Amin S, Broyde S, Geacintov N, and Patel DJ (2000) Accomodation of S-cis-tamoxifen-N2- guanine adduct with a bent and widened DNA minor groove. J Mol Biol 302:377-393.
32. Stanley LA, Carthew P, Davies R, Higginson F, Martin E, and Styles JA (2001) Delayed effects of tamoxifen in hepatocarcinogenesis-resistant Fisher 344 rats as compared with susceptible strains. Cancer Lett 171:27-35.
33. Stygar D, Murayitskaya N, Eriksson B, and Sahlin L (2003) Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol 1:40-47.
34. 2-deoxyguanosinyl-)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 59:2091-2095.
35. 32P- Postlabeling/polyacrylamide gel electrophoresis analysis: application to the detection of DNA adducts. Chem Res Toxicol 15:305-311.
36. Tucker MJ, Adam HK, and Patterson JS (1984) Tamoxifen, in Safety Testing of New Drugs (Laurence DR, McLean AEM, and Weatherall M eds) pp 125-161. Academic Press, New York.
37. Umemoto A, Komaki K, Monden Y, Suwa M, Kanno Y, Kitagawa M, Suzuki M, Lin CX, Ueyama Y, Momen MA, et al. (2001) Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. Chem Res Toxicol 14:1006-1013.
38. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Diepenhorst FW, van den Belt-Dusebout AW, and van Tinteren H (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452.
39. Westra JG, Kriek E, and Hittenhausen H (1976) Identification of the persistently bound form of the carcinogen N-acetyl-2-aminofluorene to rat liver DNA in vivo. Chem-Biol Interact 15:149-164.
40. White IN, de Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, and Phillips DH (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197-2203.